Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE In this study, on the basis of the crystal structure of K-Ras, 21 analogues (TKR01-TKR21) containing urea or thiourea were rationally designed, which can effectively inhibit the lung cancer cell A549 growth. 31851852

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE Despite substantial progress in lung cancer immunotherapy, the overall response rate in KRAS-mutant lung adenocarcinoma (ADC) patients remains low. 31744829

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE A total of 1271 small molecules were screened in KRAS-mutant and wild-type lung cancer cell lines. 30862488

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE Activated KRAS is frequently observed and paralleled by inactivating of tumor suppressors in lung cancer, while the mechanisms remained elusive. 30906631

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE Here, we show that long-term supplementation with the antioxidants N-acetylcysteine and vitamin E promotes KRAS-driven lung cancer metastasis. 31257027

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE Combined mTOR, IGF1R, and MEK inhibition inhibits the principal signaling pathways required for the survival of KRAS-mutant cells and produces marked tumor regression in three different KRAS-driven lung cancer mouse models. 31534020

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE Except for the detection of ERBB2 amplification and KRAS mutation in two patients, no other classic lung cancer driver mutations were detected. 31659278

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE To begin with, we developed a pipeline to utilize a set of computational tools in order to obtain the most deleterious nsSNPs (Q22K, Q61P, and Q61R) associated with lung cancer in the human KRAS gene. 31117243

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE Our findings demonstrate that the miR-148a-3p may play a significant role in NSCLC including the kind of lung cancer with K-Ras gene mutation, and it exerted the tumor inhibitor function by targeting SOS2. 30536836

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE KRAS mutations may act as a resistance mechanism to MET inhibition in MET dependent lung cancer. 31200822

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12). 31668570

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE Lung cancer cell lines with KRAS mutation were relatively more sensitive to KRA-533 than cell lines without KRAS mutation. 30971271

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE Although the effects of the combination vary, the combined therapeutics are one of the best options at present to treat KRAS mutant lung cancer. 31475900

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE Since mutated KRAS has been implicated in the development of various cancers including lung cancer, we tested a mutant-allele specific siRNA against KRAS<sup>G12S</sup>, in A549 cells. 30771430

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE Here we show that genetic inhibition of SHOC2 suppresses tumorigenic growth in a subset of KRAS-mutant NSCLC cell lines and prominently inhibits tumour development in autochthonous murine KRAS-driven lung cancer models. 31182717

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE Collectively, these results uncover collateral vulnerabilities co-occurring with drug resistance and tumor heterogeneity, informing novel therapeutic avenues for KRAS-mutant lung cancer. 31431614

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele. 30366101

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. 30833304

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE Our study shows that TTF-1 sensitizes the KRAS-mutated A549 and NCI-H460 lung cancer cells to cisplatin, a common chemotherapy used to treat lung cancer. 31142791

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE We performed genome-scale loss-of-function CRISPR-Cas9 screens in the presence of a MEK1/2 inhibitor (MEKi) in KRAS-mutant pancreatic and lung cancer cell lines and identified genes that cooperate with MEK inhibition. 31577942

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE The impact of EGFR and KRAS mutations in Brazilian lung cancer remains poorly explored. 30824880

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 GeneticVariation BEFREE These results pinpoint mTOR as a mechanism of resistance to chemotherapy in KRAS-mutant lung cancer and validate a rational and readily translatable strategy that combines mTOR inhibitors with standard chemotherapy to treat KRAS-mutant adenocarcinoma, the most common and deadliest lung cancer subset. 30171261

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 AlteredExpression BEFREE Together, our results suggest that mutant KRAS promotes RAD51 expression to enhance DNA damage repair and lung cancer cell survival, suggesting that RAD51 may be an effective therapeutic target to overcome chemo/radioresistance in KRAS mutant cancers.[BMB Reports 2019; 52(2): 151-156]. 30638176

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE Our results indicate that REG4 plays an important role in KRAS-driven lung cancer pathogenesis and is a novel biomarker of lung adenocarcinoma subtype. 31428934

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.700 Biomarker BEFREE Taken together, these results provide a novel mechanistic understanding of how the IKKβ pathway affects human lung tumorigenesis, indicating that IKKβ promotes KRAS-induced angiogenesis both by cancer cell-intrinsic and cancer cell-independent mechanisms, which strongly suggests IKKβ inhibition as a promising antiangiogenic approach to be explored for KRAS-induced lung cancer therapy. 30885340

2019